In its second drug-device deal of 2015, Mallinckrodt has agreed to acquire autologous immunotherapy developer Therakos for approximately US$1.325 B in order to expand its hospital business. Therakos’ extracorporeal photopheresis technology platform is approved in the US for the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma. The transaction is in line with Mallinckrodt’s growth by acquisition strategy and follows the company’s purchases of Cadence Pharmaceuticals, Questcor Pharmaceuticalsand Ikaria.